Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05557565
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
Phase 2
Completed
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT05554913
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05555212
- Locations
- 🇨🇳
Qilu Pharmaceutical.Co.,Ltd, Jinan, Shandong, China
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Not Applicable
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05531994
- Locations
- 🇨🇳
Haikou People's Hospital, Haikou, Hainan, China
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Not Applicable
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05528198
- Locations
- 🇨🇳
Haikou People's Hospital, Haikou, Hainan, China
Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors Harboring MAPK Pathway Alterations
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05488821
- Locations
- 🇨🇳
Shandong Cancer Hospital, Shandong, China
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Phase 3
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 632
- Registration Number
- NCT05487391
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT05461287
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants
Phase 1
- Conditions
- COVID-19
- Interventions
- Drug: QLS1128 C-Dose 1~3 and RitonavirDrug: QLS1128 D-Dose 1 and RitonavirDrug: QLS1128 A-Dose 1~5 and Ritonavir
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05458076
- Locations
- 🇨🇳
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Phase 3
Recruiting
- Conditions
- METASTATIC CERVICAL CANCER
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 498
- Registration Number
- NCT05446883
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China
© Copyright 2025. All Rights Reserved by MedPath